Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1080

1.

A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer.

Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, Giovannucci EL, Ma J.

PLoS Med. 2007 Mar;4(3):e103.

2.

A prospective study of plasma vitamin D metabolites, vitamin D receptor gene polymorphisms, and risk of hypertension in men.

Wang L, Ma J, Manson JE, Buring JE, Gaziano JM, Sesso HD.

Eur J Nutr. 2013 Oct;52(7):1771-9. doi: 10.1007/s00394-012-0480-8. Epub 2012 Dec 21.

3.

Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians.

Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, Hennekens CH, Hunter DJ.

Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):385-90.

4.

Vitamin D receptor protein expression in tumor tissue and prostate cancer progression.

Hendrickson WK, Flavin R, Kasperzyk JL, Fiorentino M, Fang F, Lis R, Fiore C, Penney KL, Ma J, Kantoff PW, Stampfer MJ, Loda M, Mucci LA, Giovannucci E.

J Clin Oncol. 2011 Jun 10;29(17):2378-85. doi: 10.1200/JCO.2010.30.9880. Epub 2011 May 2.

5.

The Fok1 vitamin D receptor gene polymorphism and 25(OH) D serum levels and prostate cancer among Jordanian men.

Atoum MF, AlKateeb D, AlHaj Mahmoud SA.

Asian Pac J Cancer Prev. 2015;16(6):2227-30.

6.

VDR FokI polymorphism is associated with a reduced T-helper cell population under vitamin D stimulation in type 1 diabetes patients.

Morán-Auth Y, Penna-Martinez M, Badenhoop K.

J Steroid Biochem Mol Biol. 2015 Apr;148:184-6. doi: 10.1016/j.jsbmb.2015.01.003. Epub 2015 Jan 7.

PMID:
25576905
7.

A prospective study of plasma 25-hydroxyvitamin D concentration and prostate cancer risk.

Deschasaux M, Souberbielle JC, Latino-Martel P, Sutton A, Charnaux N, Druesne-Pecollo N, Galan P, Hercberg S, Le Clerc S, Kesse-Guyot E, Ezzedine K, Touvier M.

Br J Nutr. 2016 Jan 28;115(2):305-14. doi: 10.1017/S0007114515004353. Epub 2015 Nov 16.

PMID:
26568368
8.

Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression.

Xu Y, Shibata A, McNeal JE, Stamey TA, Feldman D, Peehl DM.

Cancer Epidemiol Biomarkers Prev. 2003 Jan;12(1):23-7.

9.

Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy.

Huang SP, Huang CY, Wu WJ, Pu YS, Chen J, Chen YY, Yu CC, Wu TT, Wang JS, Lee YH, Huang JK, Huang CH, Wu MT.

Int J Cancer. 2006 Oct 15;119(8):1902-7.

10.

Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk.

Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E.

Prostate. 2007 Jun 15;67(9):911-23.

PMID:
17440943
11.

Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China.

Chokkalingam AP, McGlynn KA, Gao YT, Pollak M, Deng J, Sesterhenn IA, Mostofi FK, Fraumeni JF Jr, Hsing AW.

Cancer Res. 2001 Jun 1;61(11):4333-6.

12.

Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk.

Ahn J, Albanes D, Berndt SI, Peters U, Chatterjee N, Freedman ND, Abnet CC, Huang WY, Kibel AS, Crawford ED, Weinstein SJ, Chanock SJ, Schatzkin A, Hayes RB; Prostate, Lung, Colorectal and Ovarian Trial Project Team.

Carcinogenesis. 2009 May;30(5):769-76. doi: 10.1093/carcin/bgp055. Epub 2009 Mar 2.

13.

Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer.

Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E.

Cancer Causes Control. 2004 Apr;15(3):255-65.

PMID:
15090720
14.

Vitamin D Receptor Gene Expression and Function in a South African Population: Ethnicity, Vitamin D and FokI.

O Neill V, Asani FF, Jeffery TJ, Saccone DS, Bornman L.

PLoS One. 2013 Jun 21;8(6):e67663. doi: 10.1371/journal.pone.0067663. Print 2013.

15.

VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men.

Torkko KC, van Bokhoven A, Mai P, Beuten J, Balic I, Byers TE, Hokanson JE, Norris JM, Barón AE, Lucia MS, Thompson IM, Leach RJ.

Clin Cancer Res. 2008 May 15;14(10):3223-9. doi: 10.1158/1078-0432.CCR-07-4894.

16.

Vitamin D receptor polymorphisms in differentiated thyroid carcinoma.

Penna-Martinez M, Ramos-Lopez E, Stern J, Hinsch N, Hansmann ML, Selkinski I, Grünwald F, Vorländer C, Wahl RA, Bechstein WO, Zeuzem S, Holzer K, Badenhoop K.

Thyroid. 2009 Jun;19(6):623-8. doi: 10.1089/thy.2008.0388.

PMID:
19499989
17.

Prospective associations between vitamin D status, vitamin D-related gene polymorphisms, and risk of tobacco-related cancers.

Deschasaux M, Souberbielle JC, Latino-Martel P, Sutton A, Charnaux N, Druesne-Pecollo N, Galan P, Hercberg S, Le Clerc S, Kesse-Guyot E, Ezzedine K, Touvier M.

Am J Clin Nutr. 2015 Nov;102(5):1207-15. doi: 10.3945/ajcn.115.110510. Epub 2015 Oct 7.

PMID:
26447153
18.

Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study.

Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL, Nimptsch K, Hollis BW, Dupre N, Platz EA, Stampfer MJ, Giovannucci E.

J Natl Cancer Inst. 2012 May 2;104(9):690-9. doi: 10.1093/jnci/djs189. Epub 2012 Apr 12.

19.

Seasonal and geographical variations in lung cancer prognosis in Norway. Does Vitamin D from the sun play a role?

Porojnicu AC, Robsahm TE, Dahlback A, Berg JP, Christiani D, Bruland OS, Moan J.

Lung Cancer. 2007 Mar;55(3):263-70. Epub 2007 Jan 17.

PMID:
17207891
20.

Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.

McKay JD, McCullough ML, Ziegler RG, Kraft P, Saltzman BS, Riboli E, Barricarte A, Berg CD, Bergland G, Bingham S, Brustad M, Bueno-de-Mesquita HB, Burdette L, Buring J, Calle EE, Chanock SJ, Clavel-Chapelon F, Cox DG, Dossus L, Feigelson HS, Haiman CA, Hankinson SE, Hoover RN, Hunter DJ, Husing A, Kaaks R, Kolonel LN, Le Marchand L, Linseisen J, McCarty CA, Overvad K, Panico S, Purdue MP, Stram DO, Stevens VL, Trichopoulos D, Willett WC, Yuenger J, Thun MJ.

Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):297-305. doi: 10.1158/1055-9965.EPI-08-0539.

Supplemental Content

Support Center